

AMENDMENT




Please amend the above-captioned application as follows:


In The Claims:

Please cancel claims 6 and 7.

Please amend the claims as follows:

1. (Amended) A cyclic tetrapeptide derivative comprising a general formula selected from the group consisting of (I), (I'), (I''), (I''') and a pharmaceutically acceptable salt thereof:





wherein each of R₁₁, R₁₂, R₂₁ and R₂₂ independently denotes hydrogen, a linear C₁-C₆-alkyl group to which a non-aromatic cycloalkyl group or an optionally substituted aromatic ring may be attached, or a branched C₃-C₆-alkyl group to which a non-aromatic cycloalkyl group or an optionally substituted aromatic ring may be attached; and

each of R₁, R₂ and R₃ independently denotes a linear C₁-C₅-alkylene group which may have a C₁-C₆ side chain, in which the side chain may form a condensed ring structure on the alkylene chain;

provided that at least one of R₁₁, R₁₂, R₂₁ and R₂₂ in general formula (I'') is a cyclohexyl methyl group.

2. The cyclic tetrapeptide derivative according to claim 1, comprising said general formula (I), or a pharmaceutically acceptable salt thereof.

3. The cyclic tetrapeptide derivative according to claim 1, comprising said general formula (I'), or a pharmaceutically acceptable salt thereof.

4. The cyclic tetrapeptide derivative according to claim 1, comprising said general formula (I''), or a pharmaceutically acceptable salt thereof.

5. The cyclic tetrapeptide derivative according to claim 1, comprising said general formula (I'''), or a pharmaceutically acceptable salt thereof.

A2 8. (Amended) A pharmaceutical composition comprising a cyclic tetrapeptide derivative or a pharmaceutically acceptable salt thereof as set forth in claim 1.

Please add the following new claims:

--10. A method of inhibiting a histone deacetylase comprising administering to a subject in need thereof a cyclic tetrapeptide derivative or a pharmaceutically acceptable salt thereof as set forth in claim 1, thereby inhibiting a histone deacetylase inhibitor.

A3 11. A method of promoting an expression of an MHC class I molecule comprising administering to a subject in need thereof a cyclic tetrapeptide derivative or pharmaceutically acceptable salt thereof as set forth in claim 1, thereby promoting an expression of an MHC class I molecule.--

RECEIVED - DEPT OF STATE
JULY 15 2001